GB2451216B - A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein - Google Patents

A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein

Info

Publication number
GB2451216B
GB2451216B GB0821386A GB0821386A GB2451216B GB 2451216 B GB2451216 B GB 2451216B GB 0821386 A GB0821386 A GB 0821386A GB 0821386 A GB0821386 A GB 0821386A GB 2451216 B GB2451216 B GB 2451216B
Authority
GB
United Kingdom
Prior art keywords
hsa
vaccine composition
viral antigen
hydrolysed protein
stabilised vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB0821386A
Other languages
English (en)
Other versions
GB0821386D0 (en
GB2451216A (en
Inventor
Krishna Murthy Ella
Victor Jerusha Augustus Harshavardhan Gutla
Krishna Mohan Vadrevu
Smita Singhania
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bharat Biotech International Ltd
Original Assignee
Bharat Biotech International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech International Ltd filed Critical Bharat Biotech International Ltd
Publication of GB0821386D0 publication Critical patent/GB0821386D0/en
Publication of GB2451216A publication Critical patent/GB2451216A/en
Application granted granted Critical
Publication of GB2451216B publication Critical patent/GB2451216B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
GB0821386A 2006-05-12 2007-05-11 A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein Active GB2451216B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN842CH2006 2006-05-12
PCT/IN2007/000190 WO2007132480A2 (en) 2006-05-12 2007-05-11 A composition useful as a vaccine

Publications (3)

Publication Number Publication Date
GB0821386D0 GB0821386D0 (en) 2008-12-31
GB2451216A GB2451216A (en) 2009-01-21
GB2451216B true GB2451216B (en) 2011-05-04

Family

ID=38578478

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0821386A Active GB2451216B (en) 2006-05-12 2007-05-11 A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein

Country Status (8)

Country Link
US (1) US9642907B2 (zh)
CN (1) CN101489587B (zh)
AU (1) AU2007251122B2 (zh)
BR (1) BRPI0711608B8 (zh)
GB (1) GB2451216B (zh)
MX (1) MX2008014391A (zh)
WO (1) WO2007132480A2 (zh)
ZA (1) ZA200809622B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9598676B2 (en) * 2009-07-13 2017-03-21 Bharat Biotech International Limited Composition useful as rotavirus vaccine and a method therefor
US10092640B2 (en) * 2011-01-05 2018-10-09 Bharat Biotech International Limited Combination heptavalent vaccine
WO2013105105A2 (en) * 2012-01-13 2013-07-18 Serum Institute Of India Ltd. Novel viral vaccine compositions and methods for preparing such vaccines
CN104507495A (zh) * 2012-04-23 2015-04-08 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
WO2014032082A1 (en) * 2012-08-27 2014-03-06 Murdoch Childrens Research Institute Modified human rotaviruses and uses therefor
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105530955A (zh) * 2013-10-03 2016-04-27 日东电工株式会社 流感疫苗干燥制剂、及流感疫苗干燥制剂的制造方法
SG11201610921PA (en) * 2014-07-18 2017-02-27 Msd Wellcome Trust Hilleman Lab Pvt Ltd A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
TWI745278B (zh) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
WO2017056101A1 (en) * 2015-09-30 2017-04-06 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
MY191286A (en) 2017-02-14 2022-06-14 Inventprise Llc Heat stable liquid rotavirus vaccine
US11110163B2 (en) 2017-02-14 2021-09-07 Inventprise, Llc Heat stable vaccines
CN108434106B (zh) * 2017-04-25 2021-07-30 广州瑞贝斯药业有限公司 一种狂犬病疫苗的冻干制剂
CN110055225A (zh) * 2018-01-18 2019-07-26 北京依生兴业科技有限公司 一种提高轮状病毒产量的方法
CN113994925B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 一种轮状病毒攻毒动物模型及其建立方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205131A (en) * 1977-12-01 1980-05-27 Burroughs Wellcome Co. Virus propagation
WO1992001784A1 (en) * 1990-07-26 1992-02-06 The Wistar Institute Of Anatomy & Biology Rotavirus reassortant vaccine
WO1996001651A1 (en) * 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
WO1999062500A1 (en) * 1998-06-03 1999-12-09 Merck & Co., Inc. Stabilizers for lyophilized vaccines
WO2002011540A1 (en) * 2000-08-03 2002-02-14 Merck & Co., Inc. Rotavirus vaccine formulations
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629399A (en) * 1967-09-05 1971-12-21 Behringwerke Ag Stable poliomyelitis vaccines
US5773009A (en) 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AU2356002A (en) * 2000-09-25 2002-04-02 Polymun Scient Immunbio Forsch Live vaccine and method of manufacture
DK1833508T3 (da) * 2004-11-19 2010-12-06 Intervet Int Bv Virusstammer og sammensætninger af PRRS-syndromet (porcint reproduktivt og respiratorisk syndrom)
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
WO2007035455A2 (en) * 2005-09-16 2007-03-29 Merial Limited Stabilizers for freeze-dried vaccines
CA2628084A1 (en) * 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205131A (en) * 1977-12-01 1980-05-27 Burroughs Wellcome Co. Virus propagation
WO1992001784A1 (en) * 1990-07-26 1992-02-06 The Wistar Institute Of Anatomy & Biology Rotavirus reassortant vaccine
WO1996001651A1 (en) * 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
WO1999062500A1 (en) * 1998-06-03 1999-12-09 Merck & Co., Inc. Stabilizers for lyophilized vaccines
WO2002011540A1 (en) * 2000-08-03 2002-02-14 Merck & Co., Inc. Rotavirus vaccine formulations
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INVITROGEN: "Basal Medium Eagle (BME) (1x) liquid" Retrieved from the Internet: URL:http://www.invitrogen.com/content.cfm?pageID=95&fuseaction=MediaForm.dsp_mediaForm&productId=4> [retrieved on 2008-01-21] *
JOURNAL OF INFECTIOUS DISEASES, Vol. 192, 2005, RI Glass et al, "Development of candidate rotavirus vaccines derived from neonatal strains in India", pages S30-S35 *
JOURNAL OF VIROLOGICAL METHODS, Vol. 29, 1990, NP Ferris et al, "Freeze-drying foot and mouth disease virus antigens. 1. Infectivity studies", pages 43-52 *
SCIENCE, Vol. 130, 1959, H Eagle, "Amino acid metabolism in mammalian cell cultures", pages 432-437 *

Also Published As

Publication number Publication date
BRPI0711608A2 (pt) 2012-08-14
BRPI0711608B1 (pt) 2019-08-20
GB0821386D0 (en) 2008-12-31
US9642907B2 (en) 2017-05-09
BRPI0711608B8 (pt) 2021-05-25
AU2007251122A1 (en) 2007-11-22
CN101489587A (zh) 2009-07-22
CN101489587B (zh) 2015-05-27
WO2007132480A2 (en) 2007-11-22
US20100068227A1 (en) 2010-03-18
GB2451216A (en) 2009-01-21
ZA200809622B (en) 2009-07-29
WO2007132480A3 (en) 2008-03-20
MX2008014391A (es) 2009-03-06
AU2007251122B2 (en) 2013-01-10
WO2007132480B1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
GB2451216B (en) A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein
EP2089053A4 (en) VACCINE COMPOSITIONS BASED ON HPV ANTIGEN FUSION PROTEIN AND USES THEREOF
GB2451014B (en) Engineered Listeria comprising a modified ActA-antigen fusion protein and its use as a vaccine
IL195683A0 (en) Recombinant viral vaccine
IL192674B (en) A vaccine containing a recombinant protein from influenza is expressed in -e. coli
HK1200180A1 (zh) 針對藍舌病毒的重組疫苗
EP1984405A4 (en) INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS
EP2062246A4 (en) CHIMERIC VIRAL VACCINES
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
IL204361A (en) A method for producing influenza virus and influenza vaccine obtained from use of said method
EP1793850A4 (en) ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
ZA200705060B (en) Recombinant Newcastle disease virus
IL203869A (en) Method of Preparing a Containing a Virus or Antigen Antigen, Various Aspects Related to This Method, Uses of a Method and Vaccination of a Split Virus Prepared by This Method
HK1138297A1 (zh) 丙型肝炎病毒 的人類抗體及其用途
EP2351581A4 (en) VACCINE COMPOSITION AGAINST MALE AND CLAUSE DISEASE AND PREPARATION METHOD THEREFOR
WO2008049974A8 (en) Peptide vaccine for influenza virus
PT2144924T (pt) Vacina de proteína de fusão
EP1871411A4 (en) EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
EP2061887A4 (en) INTRODUCTION SYSTEM FOR VACCINATED VACCINATOR
EP1961814A4 (en) RECOMBINANT POLYVALENT VACCINE
GB0615635D0 (en) Immunogenic proteins and uses thereof
HK1219052A1 (zh) 針對典型性豬瘟病毒的嵌合疫苗抗原
IL195525A (en) A vaccine that contains a replicin peptide
EP1871786A4 (en) PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS
PL2285952T3 (pl) Nowe białka fuzyjne i ich zastosowanie do wytwarzania szczepionek przeciwko zapaleniu wątroby typu C